Seeking Alpha

Leerink says there's potentially still a chance of an eventual sale of Allscripts (MDRX -16%),...

Leerink says there's potentially still a chance of an eventual sale of Allscripts (MDRX -16%), despite yesterday's statement by the company regarding the conclusion of its strategic review process and decision not to put itself up for sale. It probably won't occur in the near term, however, so consequently the firm predicts the stock will continue to face significant pressure. It reduces its target range to $8 - $9 from $12 - $14.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|